APLS

NASDAQ · Biotechnology

Apellis Pharmaceuticals Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$17.72

+0.49 (+2.84%)

As of Mar 25, 9:59 PM ET ·

Analyst Consensus

Buy

Analysts

High

Coverage

Buy 20 69%

Hold 8 28%

Sell 1 3%

Price Target

Analyst Price Target +27.2% upside

Low Target $12.93

Average Target $22.54

High Target $29.12

Current Price $17.72

Current
$17.72

Target
$22.54

$12.93 $22.54 avg $29.12

Scenario Analysis

Bear Case

$12.93

-27.0%

Low target

Base Case

$22.54

+27.2%

Avg target

Bull Case

$29.12

+64.3%

High target

Risk/Reward

2.4x

Favorable

Price in Context

52-Week High

$30.48

-41.9% from high

52-Week Low

$16.10

+10.1% from low

50-Day SMA

$23.47

-24.5% vs SMA

200-Day SMA

$22.25

-20.4% vs SMA

RSI (14)

47.9

Neutral

Target vs 52W High

$22.54

-26.0% vs high

Peer Consensus — Biotechnology

Stock	Consensus	Analysts	Buy %	Target	Upside
ABBV Abbvie Inc	Buy	39	69%	$257.58	+24.3%
AMGN Amgen Inc	Hold	42	50%	$190.87	-46.1%
GILD Gilead Sciences Inc	Strong Buy	37	81%	$362.68	+162.3%
VRTX Vertex Pharmaceuticals Inc	Strong Buy	39	79%	$438.34	-3.7%
REGN Regeneron Pharmaceuticals	Strong Buy	36	75%	$76.80	-89.8%
ALNY Alnylam Pharmaceuticals Inc	Strong Buy	36	78%	$102.31	-68.9%
INSM Insmed Inc	Strong Buy	26	92%	$143.40	-3.3%
NTRA Natera Inc	Strong Buy	27	89%	$142.91	-27.6%